| IBIO INC. DL -,001 |
| USA |
| Gesundheit |
| US4510337086 / A3E2GR |
| 0JV0 (Frankfurt) |
| FRA:0JV0, ETR:0JV0, 0JV0:GR |
| - |
| https://ibioinc.com/ |
|
iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiome..
>Volltext.. |
| 59.25 Mio. EUR |
| 15.72 Mio. EUR |
| 0.26 Mio. EUR |
| -18.95 Mio. EUR |
| -21.43 Mio. EUR |
| -0.87 EUR |
| 2.12 Mio. EUR |
| 24.84 Mio. EUR |
| -16.14 Mio. EUR |
| 8.93 |
| -20% |
| -28.15% |
| - |
| - |
| - |
| - |
| IBIO |
| 04.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|